PepScribe

Guide · Peptide stacking

Sermorelin and GHK-Cu: what the research says about stacking these peptides. - Reddit

Last updated July 1, 2026

More: Clinical standards · Pharmacy partners

Sermorelin and GHK-Cu appear together frequently in peptide therapy discussions because they address distinct but complementary biological domains. Sermorelin works at the pituitary level to stimulate growth hormone release; GHK-Cu is a naturally occurring copper-binding tripeptide studied for tissue maintenance and repair signaling. This guide covers the research basis for both and what you need to know before discussing a combination protocol with a clinician.

Quick answer

Sermorelin and GHK-Cu are sometimes discussed together because they target distinct pathways: sermorelin is a Category 1GHRH analog that stimulates the pituitary’s own growth hormone release, while GHK-Cu (copper peptide) is a naturally occurring tripeptide studied for tissue repair and skin maintenance—but combining them is an individualized clinical decision, not a standardized regimen with combination-specific trial data.

Injectable GHK-Cu sits in a regulatory gray zone and requires a clinician-supervised program consultation rather than a direct peptide order, so any stacking approach should be reviewed by a licensed clinician.

Key takeaways

  • Sermorelin is Tier 1: legally compoundable by licensed 503A pharmacies in the USA with a clinician prescription.
  • GHK-Cu is a 3-amino-acid copper-binding tripeptide that occurs naturally in plasma (~200 ng/mL in young adults) and declines with age.
  • Injectable GHK-Cu is in a regulatory gray zone—removed from FDA Category 2 in April 2025but not granted Category 1—so access runs through a program consultation, not a peptide checkout.
  • There is no published clinical trial on the sermorelin + GHK-Cu combination specifically; stacking is an individualized clinical decision.
  • Topical copper-peptide skincare is a separate product category from injectable GHK-Cu, with different regulatory and safety status.

Weighing a combination protocol? A licensed clinician can review your goals and history and explain what is actually appropriate for you.

Talk to a clinician

Available: PepScribe offers a topical GHK-Cu cream. The regulatory notice below concerns the injectable form only.

Regulatory notice: Injectable GHK-Cu is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. Injectable GHK-Cu is not offered by PepScribe. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.

On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including injectable GHK-Cu. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that injectable GHK-Cu’s legal status has changed or that PepScribe will offer it in the future.

What is sermorelin, the growth hormone secretagogue?

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary gland to release growth hormone. Unlike exogenous recombinant human growth hormone (rhGH), sermorelin works by stimulating the pituitary’s own growth hormone production. This preserves the natural pulsatile release pattern and the pituitary’s feedback mechanisms.

Sermorelin has been studied since the 1970s and 1980s, with a substantial published literature on its effects on growth hormone secretion in healthy adults and older adults. It is a Category 1 bulk drug substance under FDA compounding rules, meaning it is legally compoundable by licensed 503Apharmacies in the United States with a prescribing clinician’s order.

Clinicians prescribing sermorelin typically use it for patients in growth hormone optimization protocols addressing body composition, recovery, and metabolic goals. The therapy requires clinician supervision because growth hormone axis modulation is not appropriate for everyone, and lab work before and during treatment is standard.

What is GHK-Cu, the copper peptide?

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a tripeptide that occurs naturally in human plasma, urine, and saliva. It binds copper ions and has been studied for its signaling role in tissue repair, skin maintenance, and anti-inflammatory response modulation. GHK-Cu levels in the body decline with age, from approximately 200 ng/mL in young adults to much lower levels in older adults.

The research literature on GHK-Cu is extensive in the context of skin biology and wound healing. Studies have examined its effects on collagen synthesis, fibroblast activity, and a range of gene expression changes associated with tissue maintenance. Work by Dr. Loren Pickart, who first identified GHK in the 1970s, provides much of the foundational literature.

It is important to distinguish between GHK-Cu formulations. Topical copper peptide products are widely available in cosmetic skincare and have a different regulatory and safety profile from injectable GHK-Cu. Injectable GHK-Cu is in a gray regulatory zone under current FDA compounding rules and requires a clinician-supervised evaluation through a program consultation rather than a direct peptide checkout.

Why do clinicians discuss sermorelin and GHK-Cu together?

The interest in combining sermorelin and GHK-Cu in protocols stems from their targeting of different aspects of tissue maintenance and repair:

  • Sermorelin addresses the growth hormone axis and the systemic signals that regulate lean mass retention, sleep quality, and metabolic function.
  • GHK-Cu addresses more localized tissue signaling, particularly in skin and connective tissue maintenance, through copper-dependent enzymatic pathways.

A patient interested in both growth hormone optimization and skin or connective tissue support might present goals that lead a clinician to consider both. The combination is not a standardized protocol with published clinical trial data specifically on the combination; it is an individualized clinical decision based on the patient’s specific goals, history, and what formulations are accessible to them.

There is no trial on this pairing — combining two peptides is an individualized clinical judgment, not a protocol you should self-assemble.

What is the regulatory difference between sermorelin and GHK-Cu access?

One practical consideration in any discussion of sermorelin and GHK-Cu together is that their access pathways are not the same.

Sermorelin is Tier 1. It is legally compoundable, has an established clinical history, and is available through licensed 503A pharmacies with a clinician prescription. You can read more about it and begin an assessment at PepScribe’s sermorelin page.

Injectable GHK-Cuis in a grayer regulatory position. It was removed from FDA’s Category 2 (prohibited compounds) list in April 2025 but has not received a formal Category 1 designation. Compounding pharmacies operating on the theory that removal from Category 2 lifts the prohibition may make it available through a clinician-supervised consultation. That consultation happens through a program evaluation, not a direct-order peptide page.

If you are interested in a protocol that includes GHK-Cu, the appropriate path is a clinician consultation where they can evaluate your individual situation and determine what is available and appropriate for you. The Longevity & Cellular Health program is the relevant PepScribe consultation pathway.

What to ask a clinician before starting

If you are researching a sermorelin and GHK-Cu stack, here are the questions worth asking in a clinician consultation:

  • What baseline labs do you need before starting sermorelin — specifically IGF-1 and a growth hormone panel?
  • Is injectable GHK-Cu accessible through your compounding pharmacy partner, and what is their source and sterility testing protocol?
  • Are there any interactions with my current medications or health history that change the risk-benefit calculation for either peptide?
  • What monitoring checkpoints do you use during a combined protocol?

A clinician who is not comfortable engaging with these questions specifically is not the right clinician for a peptide stacking protocol. The complexity warrants someone who has direct experience with growth hormone secretagogue protocols and is current on the regulatory landscape for gray-zone peptides.

Frequently asked questions

What is the sermorelin and GHK-Cu stack?

Stacking refers to using two or more peptides simultaneously as part of a clinician-supervised protocol. Sermorelin is a growth hormone-releasing hormone analog that stimulates the pituitary to release growth hormone. GHK-Cu (copper peptide) is a naturally occurring plasma tripeptide studied for tissue maintenance. They target distinct mechanisms, which is the rationale for combining them in some protocols.

Is sermorelin FDA-approved for compounding?

Sermorelin is a Category 1 bulk drug substance, meaning licensed 503A compounding pharmacies in the United States may legally compound it with a clinician's prescription. It has a well-established clinical use history and is one of the most researched compoundable growth hormone secretagogues.

What is GHK-Cu used for clinically?

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is studied in the literature for skin and connective tissue maintenance, wound healing support, and anti-inflammatory signaling. It is found naturally in human plasma and declines with age. Injectable GHK-Cu is a gray-zone compound under current FDA compounding rules; topical formulations have different regulatory status.

Can you stack sermorelin with GHK-Cu?

This is a question for a prescribing clinician. Combination protocols depend on your individual health history, goals, current medications, and which formulations are accessible through your pharmacy. A clinician familiar with peptide therapy can assess whether a combination approach makes sense for your situation.

What are the access differences between sermorelin and GHK-Cu injectable?

Sermorelin is Tier 1 — available through licensed 503A pharmacies with a clinician prescription via standard DTC peptide therapy platforms. Injectable GHK-Cu is in a gray regulatory zone. Access to injectable GHK-Cu requires a clinician-supervised consultation that routes through a program-level evaluation rather than a direct peptide checkout.

References

  1. Growth Hormone-Releasing Hormone: Clinical Studies and Therapeutic Aspects. Endocrine Reviews (Thorner et al.), via PubMed (1986).
  2. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International (Pickart et al.), via PubMed Central (2015).
  3. Growth Hormone-Releasing Hormone Analogues in Healthy Adults and in Older Adults. Journal of Clinical Endocrinology & Metabolism (Corpas et al.), via PubMed (1992).

Talk to a clinician about your peptide therapy goals.

3-minute assessment. A licensed practitioner reviews your history and recommends a protocol — sermorelin, combination approaches, or whatever the evidence supports for your situation.

Take the free assessmentLearn about sermorelin